• 1
    Cohen Stuart SR, Schuurman R, Burger DM et al. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). AIDS 1999; 13: F53F58.
  • 2
    Feinberg J, Greenberg RN, Goodrich J et al. Saquinavir soft gel capsule (SQV-SGC) bid regimen long term follow-up analysis (TIDBID study). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy September 2000 [Abstract 541].
  • 3
    Lalezari J, Feinberg J, Sension M et al. TIDBID study 48 week analysis: Fortovase (FTV) TID regimen compared with FTV BID or FTV + NFV BID regimens in HIV-1 infected patients. 13th World AIDS Conference, Durban, South Africa, 2000 [Abstract TUPeB3229].
  • 4
    Piketty C, Race E, Castiel P et al. Efficacy of a five drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999; 13: F71F77.
  • 5
    Montaner J, Saag M, Schwartz R. Pharmacokinetic and safety evaluations of a once daily regimen of saquinavir soft gel capsules (SQV) in HIV infected antiretroviral naive patients. Third European Symposium on the Clinical Implications of HIV Drug Resistance. Frankfurt, Germany, February 2001 [Abstract 043].
  • 6
    Cardiello P, Van Heeswijk RP, Hassink E et al. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 Study. J Acquir Immune Defic Syndr 2002; 29: 464470.
  • 7
    Castagna A, Dragsted U, Chave J-P et al. The interim analysis of a phase IV randomised, open-label, multicentre trial to evaluate safety and efficacy of indinivar/ritonavir (800 mg/100 mg bid) vs saquinavir/ritonavir (1000 mg/100 mg bid) in adult HIV-1 infection: MaxCmin1 trial. 9th Conference on Retroviruses and Opportunistic Infections. Washington, Seattle, USA, February 2002 [Abstract 450].
  • 8
    Roche Registration Ltd. Invirase (saquinavir mesylate) hard gelatin capsules. Complete Product Information 2002.
  • 9
    Roche Registration Ltd. Fortovase (saquinavir) soft gelatin capsules. Complete Product Information 2002.
  • 10
    Hsu A, Granneman GR, Cao G et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63: 453464.
  • 11
    Buss N, Snell P, Bock J, Hsu A, Jorga K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 2001; 52: 255264.
  • 12
    Kilby J, Hill A, Buss N. The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects. HIV Med 2002; 3: 18.
  • 13
    Kurowski M, Arslan A, Moecklinghoff C, Sawyer W. Comparative pharmacokinetics of twice daily (BID) Fortovase®/ritonavir and Invirase®/ritonavir. 2nd International Workshop on Clinical Pharmacology of HIV Infection. Noordwijk, The Netherlands, February 2001 [Abstract 3.2].
  • 14
    Knebel N, Sharp S, Madigan M. Quantification of the anti-HIV drug saquinavir by high-speed on-line high-performance liquid chromatography/tandem mass spectrometry. J Mass Spectrom 1995; 30: 11491156.
  • 15
    Cardiello P, Monhaphol T, Mahanontharit A et al. Pharmacokinetics of once daily saquinavir-hard gel caps (SQV-HGC) and saquinavir-soft gel caps (SQV-SGC) boosted with ritonavir (RTV) in HIV-1+ Thai patients: HIV NAT001.4 substudy. 3rd International Workshop on Clinical Pharmacology of HIV Therapy. Washington DC, USA, April 2002 [Abstract 1.2].
  • 16
    O'Brien W, Atkinson T, Han X, Soya M, East J. Combination therapy with indinavir and ritonavir in antiretroviral-experienced patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, California, USA, September 1999 [Abstract 2209].
  • 17
    Saah A, Winchell G, Seniuk G, Deutsch P. Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV) ritonavir (RTV) combinations in healthy volunteers. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, January/February 1999 [Abstract 362].
  • 18
    Hsu A, Granneman GR, Bertz BJ. Ritonavir clinical pharmacokinetics and interaction with other HIV agents. Clin Pharmacokinet 1998a; 35: 275291.
  • 19
    Mitsuyasu RT, Skolnik PR, Cohen SR et al. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. AIDS 1998; 12: F103F109.
  • 20
    Martindale. The Extra Pharmacopoeia. London, Royal Pharmaceutical Society, 1996.
  • 21
    Cardiello P, Srasuebkul P, Hassink E et al. HIV NAT. 001.3: The efficacy, safety and immunological changes of once-daily saquinavir-soft gel capsules 1600 mg/ritonavir 100 mg plus dual nucleosides in patients who had an undetectable viral load after 3 years of treatment. 9th Conference on Retroviruses and Opportunistic Infections. Washington, Seattle, USA, February 2002 [Abstract 549–T].
  • 22
    Shevitz A, Wnake C, Falutz J, Kotler D. Clinical perspectives on HIV–associated lipodystrophy syndrome: an update. AIDS 2001; 15: 19171930.
  • 23
    Dale E, Manuney J, Uffelman K, Stevens M, Grosso R. Incidence of lipodystrophy on START (Selection of thymidine analog regimen therapy) studies. The 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, USA, June 1999 [Abstract 30].
  • 24
    O'Brien W, Rojo D, Acosta E et al. Switch of saquinavir 400 mg/ritonavir 400 mg to saquinavir 1000 mg/ritonavir 100 mg during BID four drug antiretroviral therapy in patients with viral load less than 200 copies/mL. 3rd International Workshop on Clinical Pharmacology of HIV Therapy. Washington DC, USA, April 2002 [Abstract 2.1].